Acrivon reported early clinical activity for its dual WEE1/PKMYT1 inhibitor ACR-2316, including a confirmed partial response during Phase 1 dose escalation, pharmacodynamic target engagement at the first two dose levels via mass spectrometry-based AP3 profiling, and approximately dose-proportional pharmacokinetics. Preclinical datasets presented at AACR-NCI-EORTC highlight differentiated pathway effects versus benchmark agents and point to PLK1 activation, alongside CDK1/2, as a driver of pro-apoptotic activity.
The company used the meeting to showcase three posters spanning its Generative Phosphoproteomics AP3 platform and ACR-2316’s mechanistic profile. One presentation introduces KaiSR, an ensemble generative AI model designed to predict kinase–substrate relationships at the kinome scale, feeding into Acrivon’s pathway-centric drug design. Another detail is global phosphoproteomic pharmacodynamics for ACR-2316 in intact cells, positioning PLK1 as a critical node in the compound’s effect profile. A third poster consolidates preclinical evidence for single-agent activity designed through AP3. Separately, the company reiterated progress on ACR-368 (prexasertib) in a potentially registrational Phase 2b in endometrial cancer, with FDA Fast Track for the drug and Breakthrough Device designation for the OncoSignature assay, and an added trial arm that removes the pre-treatment biopsy requirement by evaluating ACR-368 plus ultra-low-dose gemcitabine in biomarker-unselected second-line patients.
Strategically, Acrivon is leaning into a platform thesis that emphasizes intracellular pathway modulation over target-centric discovery. AP3’s readouts are being embedded in both design and development: using mass-spec phosphoproteomics as an in-clinic biomarker for target engagement, and using AI-driven kinase–substrate mapping to prioritize compounds with multi-node pathway effects. ACR-2316’s deliberate engagement of WEE1/PKMYT1 with concomitant PLK1 activation signals a bet on mechanistically coherent apoptosis in tumor cells as a route to single-agent efficacy in a class where others have often pivoted to combinations due to modest monotherapy traction or hematologic toxicity.
For clinical operations, the approach cuts both ways. Serial pharmacodynamic profiling and proteomic assays can harden scientific signal and de-risk late-stage design, but they add biopsy logistics, central lab coordination, and data integration complexity. The ACR-368 all-comer arm without pre-treatment biopsy acknowledges practical enrollment frictions and may preview a hybrid model: rigorous PD assessment during early development to establish a mechanism, followed by more pragmatic inclusion criteria once a regimen and signal are defined. Sites should anticipate specialized sample handling and variable turnaround times tied to proteomic workflows; CROs and central labs may see demand for validated mass-spec pipelines and informatics to support regulatory-grade evidence. Regulators have already telegraphed receptivity to non-genomic diagnostics via Breakthrough Device status for OncoSignature, but reproducibility, assay standardization, and clinical utility will be scrutinized across indications.
The near-term watchlist centers on ACR-2316’s first efficacy dataset in AP3-selected tumor types later this year: objective response rate, durability, dose-limiting toxicities, and whether phosphoproteomic signatures correlate with benefit at the recommended Phase 2 dose. Clarity on dosing schedule and hematologic safety will determine the feasibility of a monotherapy path versus an early pivot to combinations with DNA-damage agents. A second question is whether Acrivon formalizes an OncoSignature-like companion for ACR-2316 and pursues device designation, which would solidify the platform’s regulatory footing but raise operational demands on testing infrastructure. Ultimately, the company is testing whether phosphoproteomic, AI-informed design can convert mechanistic differentiation into clinical differentiation in a competitive DNA damage response space; execution will hinge on balancing assay-driven precision with trial pragmatism at scale.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
